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Abstract
Conventional preoperative chemotherapy regimens have only limited efficacy in
hormone receptor positive (HR+) breast cancer and new approaches are
needed. We hypothesized that capecitabine, which is effective in metastatic
breast cancer, may be an active preoperative treatment for HR+ breast cancer.
Women with HR+, HER2-negative operable breast cancer received capecitabine,
2000 mg/m2 daily in divided doses for 14 days, followed by a 7-day rest period.
Treatment was repeated every 21 days for a total of four cycles. The primary
endpoint of the study was to determine the rate of pathological complete
response (pCR). Because of slow accrual, the study was closed after 24 patients
were enrolled. Three patients had a complete clinical response, and eight
patients had a partial clinical response, for an overall clinical response rate of
45.8%. There were no cases of pCR. Of the 22 patients who had pathological
response assessment by the Miller–Payne grading system, there were six grade 3
responses, and no grade 4 or 5 responses. Toxicity was manageable: the only
grade 3 toxicities observed were one case each of diarrhea, palmar plantar ery-
throdysesthesia, hypokalemia, and mucositis. There was no association between
baseline levels, or change in level from baseline to cycle 1, or from baseline to
time of surgery, of thymidine phosphorylase (TYMP), thymidylate synthase
(TYMS), dihydropyrimidine dehydrogenase (DPYD), or Ki67 and pathological,
clinical, or radiographic response. Preoperative capecitabine is a well-tolerated
regimen, but appears not lead to pCR when used as monotherapy in HR+
breast cancer.
Introduction
Hormone receptor positive (HR+) breast cancer (defined
as estrogen receptor [ER] and/or progesterone receptor
expressing tumors) accounts for 60–70% of breast can-
cers. While chemotherapy has a role in the treatment of
HR+ breast cancer, there is compelling evidence that it is
less effective in HR+ tumors than in hormone receptor
negative (HR) tumors, making treatment decisions
about the use of chemotherapy complex. A retrospective
subset analysis of three consecutive randomized trials
conducted by the Cancer and Leukemia Group B (CAL-
GB) found that patients with node-positive HR breast
cancer benefited more from recent improvements in adju-
vant chemotherapy than do those with HR+ tumors [1].
In that study, the absolute improvement in 5-year dis-
ease-free survival (DFS) was 22.8% for HR patients, as
compared with only 7.0% for HR+ patients, and the
improvement in overall survival (OS) was 16.7% and
4.0%, respectively. More direct evidence comes from
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analyses of patients treated with preoperative chemo-
therapy. The European Cooperative Trial in Operable
breast cancer (ECTO) investigated the efficacy of doxoru-
bicin/paclitaxel followed by cyclophosphamide, metho-
trexate, and fluorouracil (CMF) and found a 12%
pathological complete response (pCR) rate in those with
HR+ breast cancer compared to a 42% pCR rate in those
with HR breast cancer [2]. This observation is further
supported by work suggesting that the probability of
patients with HR tumors obtaining a pCR is signifi-
cantly higher than those with HR+ tumors [3–5]. Data
from these studies demonstrate that patients with HR+
breast cancers derive only minimal benefit from standard
chemotherapy, suggesting other treatment approaches
must be explored. Preoperative treatment provides an
optimal setting to investigate alternative therapeutic
options for HR+ breast cancer.
Capecitabine has significant antitumor activity in meta-
static breast cancer, with response rates of ~25% [6, 7].
At the time this trial was initiated, there were data from a
randomized phase II study comparing single-agent cape-
citabine to CMF in patients with metastatic breast cancer
who were age 55 or older demonstrating the response rate
to capecitabine alone was superior to CMF (25% vs.
16%). These data suggested that capecitabine may be an
alternative to combination chemotherapy.
Given the limited benefit seen from standard chemo-
therapy in HR+ breast cancer, identifying less toxic,
more effective regimens is of interest. Capecitabine has a
favorable safety profile, and its efficacy in the metastatic
setting is encouraging, making it an ideal candidate.
Capecitabine, a 5-fluorouracil (5-FU) prodrug, was
designed to preferentially deliver active 5-FU to tumor
cells. This selectivity arises from the differential expres-
sion of thymidine phosphorylase (TYMP) which converts
capecitabine to 5-FU and which has significantly higher
activity in cancer cells than in normal tissue [8, 9].
Because TYMP is required to convert capecitabine to 5-
FU, it is rational to hypothesize that the clinical
response to capecitabine is dependent on intratumoral
TYMP levels. That is, tumors with higher levels of intra-
tumoral TYMP may be more likely to respond to cape-
citabine [10]. Conversely, because thymidylate synthase
(TYMS) is the molecular target of 5-FU, tumors with
higher levels of TYMS may be relatively resistant to
capecitabine. Similarly, tumors with higher levels of di-
hydropyrimidine dehydrogenase (DPYD) may also be less
responsive to capecitabine because this enzyme is chiefly
responsible for 5-FU degradation and thus higher levels
of DPYD may lead to lower levels of intratumoral 5-FU.
The preoperative setting is an ideal situation to not only
test efficacy, but also explore biomarkers of response to
capecitabine.
Methods
Patients
A single-arm, open-label, phase II trial was conducted in
women with newly diagnosed, untreated, operable breast
cancer at Dana-Farber Cancer Institute, Brigham and
Women’s Hospital, Faulkner Hospital, and Beth Israel
Hospital (all in Boston, MA). Eligible patients were
≥18 years who were diagnosed with operable invasive
breast cancer. Patients were required to have a primary
tumor ≥1 cm by radiographic imaging and/or palpation.
Patients with bilateral cancers were eligible provided that
at least one primary tumor met eligibility requirements.
Tumors were required to express ER and/or progesterone
receptor by immunohistochemistry (tumors with any
positive staining were considered eligible), and be HER2-
negative. Patients were required to be without evidence of
metastatic cancer, and have an ECOG performance status
of 0 or 1. Key exclusion criteria included patients
with evidence of inflammatory breast cancer, known
dihydropyrimidine dehydrogenase (DPYD) deficiency,
uncontrolled intercurrent illness, and malabsorption syn-
drome.
Study treatment
Patients received treatment with oral capecitabine
2000 mg/m2 divided into twice daily dosing for 14 consec-
utive days, followed by a 7-day rest period. Treatment was
repeated every 21 days for a total of four cycles (1
cycle = 21 days). The dose of capecitabine was rounded
up to the nearest dose that could be delivered with
500 mg tablets. The dose was recalculated based on body
surface area prior to the start of each cycle. All patients
underwent pretreatment sentinel node evaluation if clini-
cally node negative, or fine-needle aspiration (FNA) of a
palpable axillary lymph node, if present. If the FNA of a
palpable axillary lymph node was negative, they then
underwent sentinel node biopsy. Patients also underwent
research core biopsies of the breast mass at baseline, and
then again 11–14 days after starting study treatment. A
breast MRI was performed at baseline and after comple-
tion of study treatment. Patients underwent primary
breast surgery, not less than 7 days and not more than
35 days after the last dose of capecitabine. Patients with a
positive pretreatment axillary FNA or sentinel lymph node
biopsy had a completion axillary dissection at time of
definitive surgery. Local therapy of breast-conserving ther-
apy or mastectomy was left to the discretion of the treat-
ing breast surgeon. Appropriate postoperative adjuvant
chemotherapy, hormonal therapy, and radiation therapy
was determined by the patient’s treating physician.
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Capecitabine doses were reduced or discontinued based
on tolerability. Events necessitating dose-reduction
included recurrent grade 3 neutropenia, grade 3 neutro-
penia with grade ≥2 fever, grade 4 thrombocytopenia,
grade ≥2 diarrhea, grade ≥2 hand–foot syndrome,
CrCl < 50, and any grade ≥2 nonhematological toxicity.
If a patient required a dose delay of capecitabine of more
than 3 weeks, the patient was withdrawn from the study
due to toxicity.
Predictive markers
Intratumoral levels of TYMP, TYMS, DPYD, and Ki67
were determined at baseline, at the end of the first cycle
of therapy, and at the time of surgery. Total RNA was
extracted from frozen OCT blocks using the RNeasy
Lipid Tissue Mini Kit according to manufacturer
instructions (Qiagen, Germantown, MD). Reverse tran-
scription to complementary DNA (cDNA) was per-
formed using QuantiTect Reverse Transcription Kit
(Qiagen).TaqMan primers and probes for TYMP, DPYD,
and TYMS genes were ordered from TaqMan Gene
Expression Assays (Hs00157317_m1, Hs00559278_m1,
Hs00426586_m1, respectively, Applied Biosystems, Foster
City, CA). b-glucuronidase was used as an internal con-
trol. A total of 50 ng of cDNA was mixed with the
TaqMan primers and probes, RNase-free water, and
TaqMan Universal PCR Master Mix. Real-time PCR
amplification and data analyses were carried out using a
StepOnePlusTM Real-Time PCR System (Applied Biosys-
tems) according to the manufacturer’s protocol. Each
sample was assayed in triplicate in a MicroAmp optical
96-well plate (Life Technologies, Grand Island, NY).
The thermocycling condition was 2 min at 50°C and a
10 min incubation at 95°C, followed by 40 two-temper-
ature cycles of 15 sec at 95°C and 1 min at 60°C.
Statistical analysis
This trial was designed as a two-stage study with a pri-
mary objective of determining the pCR rate following
four cycles of preoperative capecitabine in women with
HR+ and HER2-negative operable breast cancer. It was
planned that in the first phase, 42 patients would be
entered, and if 0 or 1 pCRs were observed, accrual would
terminate. If two or more pCRs were observed, another
38 patients would be entered, for a total of 80 patients. If
a total of six or greater pCRs were observed out of 80
patients, the treatment would be declared worthy of fur-
ther study. There would be a 50% chance of stopping
accrual early if the true pCR rate was 4%, a 37% chance
of stopping accrual early if the true pCR rate was 5%,
and a 7% chance of stopping early if the true pCR rate
was 10%. Overall, there was a 10% probability of declar-
ing the study regimen worthy of further study if the true
pCR rate was 4% and an 80% probability if the true pCR
rate was 10%. The study, however, was terminated early
due to slow accrual, with 24 patients enrolled. The 95%
confidence intervals of the response rates were calculated
using Wilson Score method [11]. Toxicity data was
reviewed and summarized by grade. Biomarker (TYMP,
TYMS, DPYD) assessments at baseline, during cycle 1
(11–14 days after start of therapy), and at surgery were
tabulated. Wilcoxon signed rank test was used to test the
difference of TYMP levelsat baseline and cycle 1.
Results
The trial opened in September 2004 and closed in Sep-
tember 2007 due to slow accrual. There were 24 patients
who enrolled in the trial. Two patients came off study
early, and therefore were not evaluable for efficacy. One
patient was taken off study after experiencing early-onset
grade 3 diarrhea and palmar-plantar erythrodysesthesia
(PPE), and another patient decided to withdraw consent
during cycle 1 of treatment due to grade 1 nausea.
Twenty-two patients went on to complete protocol treat-
ment.
Of the 24 patients enrolled, 14 patients (58%) had evi-
dence of nodal positivity at baseline, either by pretreat-
ment sentinel node procedure or FNA of a palpable
lymph node. The median tumor size by MRI imaging at
baseline was 3.4 cm, with 83% of patients having tumors
that were greater than 2 cm. All patients had HR-positive,
HER2-negative tumors, and 75% were histologically grade
2 or higher. (Table 1).
Treatment was generally well tolerated, with the most
common toxicities being PPE, diarrhea, anemia, and nau-
sea. There were only four grade 3 events (PPE, diarrhea,
hypokalemia, and mucositis) with no grade 4 events.
(Table 2).
There were no pCRs among the 24 patients (pCR rate
0%, 95% CI: 0–13.8). All cases were centrally reviewed
for Miller–Payne response [12]. This grading system is
used to assess pathological response of the tumor in the
breast after preoperative chemotherapy. A grade 1
response indicates there was no change in the overall cel-
lularity of the tumor; a grade 2 response indicates there
was up to a 30% loss in overall cellularity; a grade 3
response indicates a 30–90% reduction in tumor cells; a
grade 4 response indicates a marked disappearance of
tumor cells such that only small clusters of widely dis-
persed individual cells remain (more than a 90% loss of
tumor cells); and a grade 5 response indicates no malig-
nant tumor cells are identifiable; ductal carcinoma in-situ
may be present. This system does not include the assess-
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ment of axillary nodes. In this study, all patients had a
Miller–Payne 3 or lower response. (Table 3).
Clinical responses were assessed after completion of
four cycles of capecitabine and prior to surgery, and there
were three cases of complete clinical response, with eight
cases of partial clinical response, consistent with a 46%
clinical objective response rate. There were no cases of
clinical progression while on study. (Table 3).
Radiographic response was assessed by MRI imaging by
comparing tumor measurements at baseline with those
obtained prior to surgery. A complete response (CR) was
defined as complete disappearance of tumor, a partial
response (PR) was defined as a greater than or equal to
30% decrease in longest diameter, progressive disease
(PD) was defined as a greater than or equal to 20%
increase in longest diameter, and stable disease (SD) was
defined as tumor measurements not qualifying as a CR,
PR, or as PD. Overall, there was a 37.5% radiographic
response rate, with no cases of CR. (Table 3).
Levels of TYMP, TYMS, DPYD, and Ki67 were assessed
at baseline, during cycle 1 (11–14 days after start of ther-
apy), and at time of surgery (Table 4). TYMP levels were
significantly higher during cycle 1(11–14 days after start
of therapy) than at baseline (P = 0.004). There was no
significant association between baseline biomarker levels
or change in biomarker level (baseline to cycle 1 or
baseline to surgery) and clinical, radiographic, or Miller–
Payne response.
Discussion
Numerous trials have investigated the use of preopera-
tive chemotherapy with the goal of improving
breast-conserving therapy rates. The National Surgical
Adjuvant Breast and Bowel Project B-18 trial demon-
strated that doxorubicin and cyclophosphamide admin-
istered as neoadjuvant or adjuvant therapy had
equivalent outcomes in terms of DFS and OS [13].
Additionally, neoadjuvant chemotherapy has been shown
to increase the rate of breast-conserving surgery (BCS)
without adversely affecting DFS or OS [14]. However,
preoperative chemotherapy produces lower rates of
pathological complete responses in HR+ breast cancers
compared to HR breast cancers [5]. Moreover, con-
ventional combination chemotherapy may be associated
with substantial toxicity. Therefore, there is a great need
Table 1. Patient characteristics.
Number of patients
(Total N = 24)
Age (years)
Median (range) 53 (29–71)
Ethnicity
Caucasian 23 (95.8%)
Hispanic 1 (4.2%)
Clinical tumor size
T1 4 (16.7%)
T2 14 (58.3%)
T3 6 (25.0%)
T4 0 (0%)
Tumor size (cm) based on baseline MRI
Median (range) 3.4 (1.0–9.0)
≤2 4 (16.7%)
2–5 15 (62.5%)
>5 5 (20.8%)
Clinical nodal status
Negative 13 (54.2%)
Positive 11 (45.8%)
Pathological nodal status
Positive 14 (58.3%)
Performed FNA only 6 (25.0%)
Performed sentinel node biopsy only 6 (25.0%)
Performed both FNA and sentinel
node biopsy
2 (8.3%)
Negative 10 (41.6%)
Performed sentinel node biopsy only 8 (33.3%)
Performed both FNA and sentinel
node biopsy
2 (8.3%)
Receptor status
ER positive 24 (100%)
PR positive 24 (100%)
HER2-negative 24 (100%)
Ki67 expression
<5 7 (29.2%)
≥5 17 (70.8%)
Grade
1 6 (25%)
2 12 (50%)
3 6 (25%)
Table 2. Toxicity of preoperative capecitabine therapy.
Toxicity
Grade 1–2,
n (%)
Grade 3,
n (%)
Grades
1–3,%
Palmar-plantar
erythrodysesthesia
19 (79.2%) 1 (4.2%) 83.3%
Diarrhea 15 (62.5%) 1 (4.2%) 66.7%
Anemia 9 (37.5%) 0 (0%) 37.5%
Nausea 9 (37.5%) 0 (0%) 37.5%
Fatigue 8 (33.3%) 0 (0%) 33.3%
Mucositis 4 (16.7%) 1 (4.2%) 20.8%
AST/ALT 4 (16.7%) 0 (0%) 16.7%
Abdominal pain 4 (16.7%) 0 (0%) 16.7%
Anorexia 3 (12.5%) 0 (0%) 12.5%
Elevated bilirubin 3 (12.5%) 0 (0%) 12.5%
Hyperglycemia 3 (12.5%) 0 (0%) 12.5%
Insomnia 3 (12.5%) 0 (0%) 12.5%
Leukopenia 3(12.5%) 0 (0%) 12.5%
Rash 3 (12.5%) 0 (0%) 12.5%
Hypokalemia 0 (0%) 1 (4.2%) 4.2%
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for effective alternatives to anthracycline and taxane-
based chemotherapy for HR+ breast cancer.
Capecitabine was postulated to be an attractive alterna-
tive to standard preoperative chemotherapy as it is gener-
ally well tolerated, and in the metastatic setting was
found to have response rates similar to CMF [6, 7]. This
study is the first to evaluate preoperative capecitabine
given as monotherapy for HR+ breast cancer. Data that
emerged after this trial completed accrual demonstrated
that standard adjuvant combination chemotherapy is
superior to capecitabine in patients with early-stage breast
cancer who are ≥65 years of age. An unplanned subgroup
analysis demonstrated that the major benefit of standard
chemotherapy occurred in patients with HR negative
breast cancer [15]. Additionally, preoperative trials have
failed to demonstrate a benefit from the addition of cape-
citabine to standard chemotherapy [16, 17]. This study
supports these findings, as preoperative capecitabine was
unable to achieve pCRs in HR+ breast cancer.
Given the small numbers of patients, and the overall
limited efficacy of the capecitabine regimen, it is difficult
to determine association of TYMP, TYMS, and DPYD with
response. Higher levels of TYMP have been associated with
higher rates of pathological response to preoperative cape-
citabine or 5-FU in colorectal cancer [18, 19], and to pro-
longed time to progression from capecitabine in
metastatic breast cancer [20, 21], but in this study, there
did not appear to be a trend with baseline TYMP and clin-
ical, radiographic, or Miller–Payne response. However, as
noted, it is difficult to draw conclusions with the small
numbers of patients in each response group.
Interestingly, there was a significant increase in TYMP
from baseline to the biopsy performed at cycle 1, but levels
decreased in the surgical specimen. This may suggest early
induction of TYMP with initiation of capecitabine therapy.
TYMP has been shown to increase in tumor samples of
patients receiving anthracycline- and taxane-based preop-
erative chemotherapy for breast cancer and this observa-
tion provided the rationale for several studies which
evaluated the addition of capecitabine to taxane-based
therapy [22–24]. TYMP expression has been significantly
associated with expression of TNF-a, IL-1a, and monocyte
chemoattractant protein (MCP)-1 [25]. It is possible that
increases in TYMP may be triggered by increases in con-
centrations of these immune mediators, which may be
stimulated by the initiation of chemotherapy.
Our results suggest that capecitabine monotherapy
appears to have limited efficacy HR+HER2-breast cancer,
consistent with other studies which have failed to identify
a role for this agent in the treatment of early-stage breast
cancer. Other approaches will need to be explored to
improve preoperative response rates in HR+, HER2-
breast cancer.
Conflict of Interest
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Table 3. Response data to preoperative capecitabine therapy.
Pathological
response
Number of
patients (%)
Pathological
complete response
rate (95% CI)
pCR 0 (0) 0 (0–13.8)
Not pCR 22 (91.7)
Unevaluable1 2 (8.3)
Best overall
response
Number of
patients (%)
Objective response
rate (95% CI)
Radiographic
CR 0 (0) 37.5 (21.2–57.3)
PR 9 (37.5)
SD 11 (45.8)
PD 2 (8.3)
Unevaluable1 2 (8.3)
Clinical
CR 3 (12.5) 45.8 (27.9–64.9)
PR 8 (33.3)
SD 11 (45.8)
PD 0 (0)
Unevaluable1 2 (8.3)
Miller–Payne
1 10 (41.7)
2 6 (25.0)
3 6 (25.0)
4 0 (0)
5 0 (0)
Unevaluable1 2 (8.3)
pCR, pathological complete response; CR, complete response; PR, par-
tial response; SD, stable disease; PD, progressive disease.
1Two patients were off treatment after Cycle 1.
Table 4. Biomarkers on tissue collected at baseline, after one cycle,
and at time of surgery.
Biomarker
Baseline
(fold expression)
Cycle 1
(fold expression)
Surgery
(fold expression)
Thymidine phosphorylase (TYMP)
N 21 17 13
Median
(range)
0.58 (0.11–1.68) 1.36 (0.41–10.79) 0.39 (0.09–1.66)
Thymidylate synthase (TYMS)
N 21 17 13
Median
(range)
0.22 (0.07–0.63) 0.32 (0.07–1.1) 0.16 (0.08–0.77)
Dihydropyrimidine dehydrogenase (DPYD)
N 21 16 13
Median
(range)
0.42 (0.11–1.76) 0.67 (0.24–1.94) 0.30 (0.15–1.19)
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